Journals / Türk Kardiyoloji Derneği Arşivi / 2017 / Cilt: 45 - Sayı: 3

Microbiota and metabolic syndrome

Mikrobiyota ve metabolik sendrom

Pages
286–296
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Healthy diet recommendations, including prebiotic and probiotic foods and the use of probiotic agents, look promising for future treatment of metabolic syndrome and cardiovascular diseases

📌 3 Key Takeaways

🎯
Objective & Hypothesis:– The role of gut bacteria in the pathogenesis and treatment of various diseases has been a focus of attention in the last 10 years.
📊
Key Findings & Data:Prevalence of diabetes, obesity, and cardiovascular diseases continues to increase, in spite of technological developments and treatment alternatives.
💡
Conclusion & Impact:Healthy diet recommendations, including prebiotic and probiotic foods and the use of probiotic agents, look promising for future treatment of metabolic syndrome and cardiovascular diseases
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

– The role of gut bacteria in the pathogenesis and treatment of various diseases has been a focus of attention in the last 10 years. Prevalence of diabetes, obesity, and cardiovascular diseases continues to increase, in spite of technological developments and treatment alternatives. Microbial dysbiosis, described as the decrease of useful bacteria and the increase of harmful bacteria, has been associated with diabetes, obesity, atherosclerosis, and metabolic syndrome. In microbial dysbiosis, increase of harmful metabolites and changes to composition of bile acids occur via carbohydrate and protein fermentation. As a result, insulin resistance pathways are activated, which initiate the processes of obesity, diabetes, and atherosclerosis. Healthy diet recommendations, including prebiotic and probiotic foods and the use of probiotic agents, look promising for future treatment of metabolic syndrome and cardiovascular diseases

Özet

İnsan gastrointestinal sisteminde bulunan bakterilerin çeşitli hastalıkların patogenezinde ve tedavisinde rol aldığı son 10 yılda ortaya çıkmış ve konu yoğun ilgi odağı olmuş- tur. Dünyada teknolojik gelişmeler ve tedavi seçeneklerinin artmasına rağmen diyabet, obezite ve kardiyovasküler hastalıklar hızla artmaktadır. Faydalı bakterilerin azalıp zararlı bakterilerin artması olarak adlandırılan mikrobiyal disbiyozisin diyabet, obezite, metabolik sendrom ve ateroskleroz ile ilişkili olduğu gösterilmiştir. Mikrobiyal disbiyozisde karbonhidrat ve proteinlerin fermantasyonu yolu ile zararlı metabolitler artmakta ve safra asitlerinin bileşiminde değişiklikler oluşmaktadır. Tüm bu nedenlerin sonucunda insülin direnci yolakları aktive olarak hem obezite ve diyabet, hem de ateroskleroz süreci hızlanmaktadır. Prebiyotik ve probiyotik gı- dalarla probiyotik ajanları içeren sağlıklı beslenme önerileri, metabolik sendrom ve kardiyovasküler hastalıkların tedavisinde gelecek vaat etmektedir.

🔖

Cite This Article

ALTUNTAŞ, Y., BATMAN, A. (2022). Microbiota and metabolic syndrome. Türk Kardiyoloji Derneği Arşivi, Cilt: 45 - Sayı: 3, 286–296. https://ajindex.com/articles/632310

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014;157:121–41
  2. Ottman N, Smidt H, de Vos WM, Belzer C.The function of our microbiota: who is out there and what do they do? Front Cell Infect Microbiol 2012;9:104
  3. Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One 2012;7:35240
  4. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003;278:11312–9
  5. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 2010;107:14691–6
  6. Rodes L, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, et al. Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol 2013;23:518–26
  7. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004;101:15718–23. 8. de Wit N, Derrien M, Bosch-Vermeulen H, Oosterink E, Keshtkar S, Duval C, et al. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am J Physiol Gastrointest Liver Physiol 2012;303:589–99
  8. Churruca I, Fernandez-Quintela A, Portillo MP. Conjugated linoleic acid isomers: differences in metabolism and biological effects. Biofactors 2009;35:105–11
  9. Houseknecht KL, Vanden Heuvel JP, Moya-Camarena SY, Portocarrero CP, Peck LW, Nickel KP, et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun 1998;244:678–82
  10. Chaplin A, Parra P, Serra F, Palou A. Conjugated Linoleic Acid Supplementation under a High-Fat Diet Modulates Stomach Protein Expression and Intestinal Microbiota in Adult Mice. PLoS One 2015;10:e0125091
  11. Davila AM, Blachier F, Gotteland M, Andriamihaja M, Benetti PH, Sanz Y, et al. Re-print of “Intestinal luminal nitro